”I’ve spent over (Rs)25-30 crore in the last seven years on research and regulatory approvals around our Bt (Bacillus thuringiensis) genes, but with this price cap, I can’t negotiate appropriate licensing fees with seed companies and I can’t competitively price my seeds. So, we are bleeding,” said K.K. Narayanan, managing director of Metahelix Life Sciences Pvt. Ltd, a Bangalore-based crop biotech firm.